KALA BIO, Inc. (Nasdaq: KALA) announced preliminary unaudited financial results for the quarter ended September 30, 2026, in a press release dated November 9, 2026. The company reported a net loss of approximately $0.8 million for the third quarter of 2026. This figure represents a significant improvement compared to the third quarter of 2025, when the company recorded a net loss of $7.6 million.
For the nine months ended September 30, 2026, KALA BIO reported a net loss of approximately $4.0 million. This compares to a net loss of $27.7 million for the same period in the prior year.
As of September 30, 2026, the company held approximately $7.0 million in cash, cash equivalents, and short-term investments, with no debt outstanding. The company stated that it has reduced its quarterly net loss by approximately 90% year over year.
KALA BIO expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, with the SEC on or about November 16, 2026. The company noted that the preliminary results are subject to the completion of financial close procedures and review by its independent registered public accounting firm, and final results may differ.
